Pivotal bioVenture Partners is a San Francisco-based venture capital firm that focuses on investing in early-stage biotechnology companies in North America and Europe. Established in 2017, the firm targets innovative therapeutic products and platforms aimed at addressing significant unmet medical needs. Pivotal bioVenture Partners invests at various stages of a company's development, from inception through mid and late-stage clinical development. The firm's team possesses a diverse range of expertise in venture capital, company building, and drug discovery, enabling them to effectively collaborate with entrepreneurs to advance their business objectives.
Partner, Board Member HotSpot Tx, Bolt Bio, Fountain Tx and Evommune
Jeni Lee
Partner
Past deals in Cayman Islands
Stealth BioTherapeutics
Convertible Note in 2018
Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of therapies targeting diseases linked to mitochondrial dysfunction. Founded in 2006 and based in George Town, Cayman Islands, the company is advancing its lead product candidate, Elamipretide, which aims to address both rare genetic and age-related mitochondrial diseases. Additionally, Stealth BioTherapeutics is developing SBT-20, a small peptide that stabilizes mitochondrial structure and function during oxidative stress, and SBT-272, a compound under evaluation for rare neurodegenerative diseases, including amyotrophic lateral sclerosis. Mitochondria play a crucial role in energy production and overall organ function, making the company's focus on these organelles significant in the biopharmaceutical landscape.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.